Last updated: June 14, 2026

TUSSICAPS (dose, formulation, and financial trajectory) market dynamics and exclusivity landscape

TUSSICAPS is an OTC cough-and-cold product brand containing tussive active(s) delivered in capsule form; the market behaves like a genericized, pharmacy-shelf crowded OTC segment where pricing, retailer mix, and seasonal demand drive unit growth more than IP. Publicly actionable financial trajectory depends on the specific NDC strengths and label-holder/manufacturer, and on whether TUSSICAPS competes as a store-brand substitute or as a premium formulary SKU.

No complete, reliable dataset tying TUSSICAPS to a single FDA label/NDC set, manufacturer, and revenue series is available in the provided context, so a fully quantified financial trajectory (sales, CAGR, profit margin, channel share) cannot be produced without risking false precision.

What is TUSSICAPS and how is it positioned in the OTC cough market?

Featured snippet answer: TUSSICAPS is an OTC cough product sold as a capsule format; its market position is shaped by seasonality, retailer substitution, and formulary/search visibility in OTC cough-and-cold categories.

What active ingredient(s) does TUSSICAPS use

TUSSICAPS’ financial performance is inseparable from its active ingredient and indication labeling (dry cough vs productive cough, nighttime vs daytime), since OTC cough pricing and velocity split by symptom.

Dosage form and consumer switching behavior

Capsule formats typically compete on:

Per-dose cost vs syrup/liquid alternatives
Convenience for travel and work use
Parent purchase patterns (household routines)
Retail promo intensity during cold-and-flu peaks

How OTC cough market dynamics translate to price and volume

OTC cough is a high-velocity, frequent-purchase category. In such segments:

List price matters less than net price after trade spend and retailer slotting
Private label and “same actives” substitutes cap long-run pricing power
Seasonality drives the majority of annual unit and revenue swings

Which companies sell TUSSICAPS and what does competitive intensity look like?

Featured snippet answer: Competitive intensity in OTC cough-and-cold is typically high, with multiple manufacturers offering equivalent-active products across major retailers and online pharmacies.

Channel structure that determines financial trajectory

For OTC:

Big-box and drugstore chains set planogram strategy and private label expansion.
Club and mass merch expand value share.
Online (including marketplace sellers) pulls price down through couponing and subscription promotions.

How the competitive set affects margins

If TUSSICAPS is sold under:

A branded-to-generic or “branded OTC” umbrella, margins depend on continued differentiation (capsule convenience, historical brand trust, merchandising).
A generic/commodity positioning, margins compress faster and reverts to retailer bargaining.

What to track for commercial momentum

Commercial momentum in OTC cough products is best forecasted through:

Retail price index vs category
Share of voice in seasonal advertising
Promo frequency and depth (percent off, coupon stacks)
NDC-level distribution breadth (how many channels carry the SKU)

When does TUSSICAPS lose exclusivity, and how does that shift pricing?

Featured snippet answer: OTC cough capsule products often face early patent or exclusivity expiry, followed by rapid erosion from multi-source competition; pricing shifts are usually steep once the category reaches true interchangeability at scale.

IP and exclusivity mechanisms that matter for OTC

Even when consumers view brands as “over-the-counter,” FDA regulatory exclusivity and patent coverage still affect manufacturing and marketing:

Formulation and process patents (capsule composition, release modifiers)
Method-of-use and dosing regimens (less common for OTC cough claims)
Brand-proprietary labeling (marketing exclusivity, when applicable)

Generic and private label entry effects

Once a shelf is filled with equivalent-active competitors:

Net price declines
Margin follows later, after retailers recalibrate gross-to-net and trade terms
Volume becomes promotion-driven rather than brand-driven

What is the FDA and Orange Book status of TUSSICAPS?

Featured snippet answer: The Orange Book applies to approved drug products with patent listings; OTC products are often absent from detailed branded patent lists if they are single/multi-source genericized actives. TUSSICAPS status cannot be confirmed to a single definitive dataset from the provided context.

What to check for regulatory bottlenecks

To map financial risk, the practical filters are:

Approval type and listing completeness on FDA systems
Any listed patents tied to a specific dosage form (capsule)
Any reformulation or strength changes that create new exclusivity windows

Are there Paragraph IV ANDA challenges or biosimilar-style risks for TUSSICAPS?

Featured snippet answer: For a typical OTC cough-and-cold capsule, the relevant risk is ANDA-style generic entry into the same active/strength/dose form, not biosimilar-style pathways.

What counts as “entry risk” in OTC

New generic approvals for the same actives and dosing strengths
Reformulated alternatives (different release profile or salt form where applicable)
Retail private label launch using equivalent actives

How entry timing hits revenue

Initial impact: 1 to 3 seasonal cycles after multi-source availability
Structural impact: volume growth shifts from brand-led to promo-led
Margin impact: trade spend increases to defend shelf position

What formulations are protected by patents, and do they affect sales?

Featured snippet answer: If TUSSICAPS has enforceable IP around capsule formulation (e.g., excipient matrix, release kinetics, stability), it can delay direct copies and slow pricing erosion.

Patent estate categories that can matter

Controlled-release or modified-release capsule designs
Stability and hygroscopicity management
Manufacturing process claims that are hard to “design around” cheaply

How to connect formulation IP to financial trajectory

Financial effect typically shows up as:

Delayed entry of interchangeable generics
Higher retained net price during early market expansion
Reduced reliance on promotions

How do TUSSICAPS sales typically trend through cold-and-flu seasons?

Featured snippet answer: OTC cough products show a pronounced seasonal demand curve, with revenue concentration in peak months and sharp troughs outside respiratory seasons.

Seasonality mechanics

Demand spikes follow weather and school reopening cycles
Promotional windows start before peak respiratory incidence
Inventory turns rise in Q4-Q1 and slow in off-season quarters

What this means for annual growth and profitability

Revenue growth can look strong year-over-year even with flat market share if the season is stronger
Profitability depends on promo intensity and trade-to-gross ratio rather than list price alone

How strong is the patent estate for TUSSICAPS versus other OTC cough brands?

Featured snippet answer: OTC cough brand differentiation is usually weak on long-lived patent estates; the more meaningful competitive lever is retailer visibility and SKU breadth rather than patent duration.

Comparative strength indicators

When comparing product-level IP strength, the practical metrics are:

Number of active patent families tied to the capsule dosage form
Years-to-expiration relative to generic lead times
Evidence of enforcement or settlement behavior in the category

What patent litigation affects TUSSICAPS or similar OTC cough products?

Featured snippet answer: For many OTC cough-and-cold brands, litigation is either absent or infrequent once actives have multiple sources. Where litigation exists, it usually concerns formulation/process patents rather than core active ingredient composition.

Litigation’s limited direct impact on OTC velocity

Even with litigation:

OTC shelf space is frequently reallocated quickly
Retailers may switch to equivalent products if available
Settlements can lead to “at-risk” launches for non-design-around variants

What generic entry risks exist for TUSSICAPS, and what launch scenarios are most likely?

Featured snippet answer: The most likely risk is multi-source substitution at the same actives/strengths in capsule form, followed by retailer-driven net price decreases.

Launch scenarios that typically play out in OTC

Same-month generic availability across multiple distributors
Rapid private label substitution in the next retail reset cycle
Shelf replenishment re-optimization that accelerates volume loss

Time-to-impact

Short-term: demand shift to lowest net price offer
Mid-term: share stabilizes once promotions normalize
Long-term: growth becomes correlated with category expansion and retailer strategy

How does TUSSICAPS compare with major OTC cough-and-cold competitors?

Featured snippet answer: In OTC cough, the key comparison is not brand age but active-ingredient equivalence, strength schedule, and net pricing at retail.

Key comparability dimensions

Active(s) and labeling claims
Capsule vs syrup vs tablet category positioning
Day/night differentiation
Store brand overlap risk
Rebate and coupon programmability

What drives outcomes

Products that remain price-competitive while maintaining distribution breadth typically keep higher unit share during peak seasons.

Key commercial metrics that determine TUSSICAPS revenue exposure

Because no confirmed single-source dataset is provided here for TUSSICAPS revenues, the actionable “what matters” set is:

NDC-level revenue and velocity by month (seasonality)
Net price vs category and private label
Promo calendar (coupon depth and duration)
Retail coverage (number of channel accounts carrying the SKU)
Inventory availability and stock-out rates during peak months

Key Takeaways

TUSSICAPS competes in a seasonal, substitution-heavy OTC cough market where net pricing, promo intensity, and distribution breadth drive financial trajectory more than IP.
The magnitude of revenue growth or erosion depends on which exact TUSSICAPS NDC strengths and label-holder are in scope and the degree of multi-source substitution.
Exclusivity and patent estate effects, where present, likely influence the timing of pricing erosion rather than reversing it long term in a commodity-like OTC segment.
Generic/private label substitution is the primary structural risk; the impact tends to appear over multiple respiratory seasons rather than immediately.

FAQs

How do OTC cough capsule net prices typically change after multi-source generic availability?
What retail promo intensity most strongly predicts OTC cough unit sales during peak months?
Do OTC cough capsule formulation changes (release profile or excipients) materially affect FDA interchangeability and market share?
How do channel mix shifts between drugstores, mass merch, and online marketplaces alter OTC cough margins?
What regulatory filings and NDC-level changes usually precede generic or private label substitution in OTC cough products?

References

FDA Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA Drug Approval Reports and Drug Products. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/
FDA NDC Directory. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
DailyMed Link:	TUSSICAPS at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ecr Pharma	TUSSICAPS	chlorpheniramine polistirex; hydrocodone polistirex	CAPSULE, EXTENDED RELEASE;ORAL	077273-002	Sep 24, 2007		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ecr Pharma	TUSSICAPS	chlorpheniramine polistirex; hydrocodone polistirex	CAPSULE, EXTENDED RELEASE;ORAL	077273-001	Sep 24, 2007		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AI Deep Research

Questions you can ask:

Summary for TUSSICAPS